Remote Kura Oncology, Inc. Jobs
Upgrade to Premium for unlimited access to the largest remote job platform
- 100,000+ Global Remote Companies
- AI Deep Matching: Find jobs where you're a top 5 candidate
- Priority Access to Recruiters as a Certified Premium Talent
0 jobs found
0 jobs found
Sort by:
Relevance
Executive Director, Head of Biostatistics
Executive Director, Head of Biostatistics
![Logo for Kura Oncology, Inc.](https://cdn-s3.jobgether.com/kuraoncologyinc%2Fprofile.webp)
10 days ago
Kura Oncology, Inc.
76% flex
Matchscore
- 300 - 342K
- Remote: California (USA), Kentucky (USA), Massachusetts (USA), Texas (USA)
Sr. Manager/Associate Director CMC Demand Planning & Vendor Management
Sr. Manager/Associate Director CMC Demand Planning & Vendor Management
![Logo for Kura Oncology, Inc.](https://cdn-s3.jobgether.com/kuraoncologyinc%2Fprofile.webp)
30+ days ago
Kura Oncology, Inc.
76% flex
Matchscore
- Full time
- 157 - 190K
- Remote: California (USA), Kentucky (USA), Massachusetts (USA), Texas (USA)
Associate Director/Director, Clinical Pharmacology
Associate Director/Director, Clinical Pharmacology
![Logo for Kura Oncology, Inc.](https://cdn-s3.jobgether.com/kuraoncologyinc%2Fprofile.webp)
23 days ago
Kura Oncology, Inc.
76% flex
Matchscore
- 182 - 254K
- Remote: California (USA), Kentucky (USA), Massachusetts (USA), Texas (USA)
Vice President of Sales
Vice President of Sales
![Logo for Kura Oncology, Inc.](https://cdn-s3.jobgether.com/kuraoncologyinc%2Fprofile.webp)
9 days ago
Kura Oncology, Inc.
76% flex
Matchscore
- Full time
- Remote: California (USA), Kentucky (USA), Massachusetts (USA), Texas (USA)
Sr Mgr/Associate Director, GMP Quality Assurance
Sr Mgr/Associate Director, GMP Quality Assurance
![Logo for Kura Oncology, Inc.](https://cdn-s3.jobgether.com/kuraoncologyinc%2Fprofile.webp)
30+ days ago
Kura Oncology, Inc.
76% flex
Matchscore
- Full time
- 136 - 188K
- Remote: California (USA), Kentucky (USA), Massachusetts (USA), Texas (USA)
Associate Director/Director, Biostatistician
Associate Director/Director, Biostatistician
![Logo for Kura Oncology, Inc.](https://cdn-s3.jobgether.com/kuraoncologyinc%2Fprofile.webp)
30+ days ago
Kura Oncology, Inc.
76% flex
Matchscore
- Full time
- Remote: California (USA), Kentucky (USA), Massachusetts (USA), Texas (USA)
Associate Director/Director, Process Engineering and Validation
Associate Director/Director, Process Engineering and Validation
![Logo for Kura Oncology, Inc.](https://cdn-s3.jobgether.com/kuraoncologyinc%2Fprofile.webp)
30+ days ago
Kura Oncology, Inc.
76% flex
Matchscore
- Full time
- Remote: California (USA), Kentucky (USA), Massachusetts (USA), Texas (USA)
New!
Do you want to see hybrid jobs?
More job openings are available if you are open to hybrid remote job positions.
Include hybrid jobs
Are you looking for a Remote Kura Oncology, Inc. Jobs?
Discover more about Kura Oncology, Inc. ?
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.